A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area

导出原文传递

翻译打印收藏纠错

作者： Keitel, W. A. ^[1] ; Potter, G. E. ^[2] ; Diemert, D. ^[2] ; Bethony, J. ^[1] ; El Sahly, H. M. ^[2] ; Kennedy, J. K. ^[3] ; Patel, S. M. ^[2] ; Plieskatt, J. L. ^[2] ; Jones, W. ^[4] ; Deye, G. ^[4] ; Bottazzi, M. E. ^[3] ; Hotez, P. J. ^[2] ; Atmar, R. L. ^[1]

作者单位： George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA ^[1] Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA ^[2] Emmes Corp, Rockville, MD USA ^[3] NIAID, DMID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA ^[4]

关键词 Schistosomiasis Schistosoma mansoni (Sm)Sm tetraspanin 2 (Sm-TSP-2)Immune responses Immunization Glucopyranosyl lipid A Adjuvant

发布时间 2020-02-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交